



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 3rd October 2019
Ein Cyf / Our Ref: 19-I-006

☎ 01639 648363

✉ FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 6th September 2019. Your request sought information relating to haemophilia and Von Willebrand.

Please provide the number of patients with the following:

Haemophilia A - 63

Haemophilia B - 6

Von Willebrand Disease (under 18 and over 18)

under 18 years -11 patient, over 18 years – 19 patients

Over the last 3 months, how many patients with Haemophilia A have been treated with:

- Advate** - 5
- Afstyla** - 0
- Elocta** - 0
- Emicizumab (Hemlibra)** - 0
- Helixate** - 0
- Kogenate** - 0
- Novoseven RT**- 0
- Novoeight** - 0
- Nuwiq**- 0
- Refacto AF** - 8
- Factor Eight Inhibitor Bypass Activity**- 0



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

If you are able to split the above by patients who have mild, moderate and severe Haemophilia, that would be useful, thanks.

Over the last year, how many patients have been treated with:

- Alphanate - 0**
- DDAVP (desmopressin) - 8**
- Haemate P- 0**
- Tranexamic acid***
- Veyvondi- 0**
- Voncento - 5**
- Willate- 0**
- Willfact- 0**
- Willfactin- 0**
- Alprolix- 0**
- BeneFIX- 0**
- Idelvion- 0**
- Refixia- 0**
- Rixubis- 0**

*Tranexamic acid is used frequently, however this is not reported centrally so we are unable to provide accurate figures for this.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

